Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study

OBJECTIVE: To compare anti-TNF dose escalation, DMARD and/or glucocorticoid intensification, switches to another biologic, and drug and drug-related costs over 12 and 18 months for rheumatoid arthritis (RA) patients initiating etanercept (ETN), adalimumab (ADA), or infliximab (IFX) in routine clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorne, Carter, Boire, Gilles, Chow, Andrew, Garces, Kirsten, Liu, Fang, Poulin-Costello, Melanie, Walker, Valery, Haraoui, Boulos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744265/
https://www.ncbi.nlm.nih.gov/pubmed/29296125
http://dx.doi.org/10.2174/1874312901711010123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744265/
https://www.ncbi.nlm.nih.gov/pubmed/29296125
http://dx.doi.org/10.2174/1874312901711010123

Ejemplares similares